Univest
Univest
  • Markets

Aarey Drugs Analyst Review 2027: A Stock That Doubled on a Business Earning ₹1.37 Crore a Quarter

  • November 17, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Aarey Drugs Analyst Review 2027: A Stock That Doubled on a Business Earning ₹1.37 Crore a Quarter

Aarey Drugs & Pharmaceuticals Stock Snapshot (16 Nov 2026 close)

  • Current Market Price (CMP): ₹111.12
  • 52-Week High / Low: ₹116.80 / ₹50.31
  • Market Capitalisation: ₹351 crore
  • P/E Ratio vs Industry P/E: 84.1 vs 52.2
  • Latest Quarter (Q2 FY27) Revenue: ₹88.62 crore (net sales)
  • Latest Quarter (Q2 FY27) Net Profit: ₹1.37 crore

Quick Answer: The Aarey Drugs analyst review 2027 has to begin with a plain fact: no brokerage publishes a rating or target on this micro-cap, so there is no Aarey Drugs share price target 2027 from analysts to cite. What the numbers show is a stock that has risen about 121% from its 52-week low of ₹50.31 to ₹111.12, while Q2 FY27 net sales were ₹88.62 crore and profit was ₹1.37 crore. Operating margin was only about 2.4%, and most of pre-tax profit came from other income. At a P/E near 84, the valuation already assumes a big improvement.

The Aarey Drugs analyst review 2027 is a study in how far a share price can move ahead of the business underneath it. Anyone searching for an Aarey Drugs share price target 2027 should know that no research house covers the stock. The useful exercise is to read the company’s own numbers and judge them against the rally.

Aarey Drugs & Pharmaceuticals closed at ₹111.12 on 16 November 2026, about 5% below its 52-week high of ₹116.80 and more than double its low of ₹50.31. This Aarey Drugs analyst review 2027 covers the latest results, how the company earns, its balance sheet, ownership changes and what will shape the Aarey Drugs stock outlook 2027.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Say in the Aarey Drugs Analyst Review 2027
  • Q2 FY27 Results in the Aarey Drugs Analyst Review 2027
  • How Aarey Drugs Makes Money
  • Growth Triggers in the Aarey Drugs Analyst Review 2027
  • Key Risks in the Aarey Drugs Analyst Review 2027
  • Aarey Drugs Analyst Review 2027: Stock at a Glance
  • Shareholding Trend
  • What to Watch After the Aarey Drugs Analyst Review 2027
  • Final Word on the Aarey Drugs Analyst Review 2027
  • Frequently Asked Questions
    • What does the Aarey Drugs analyst review 2027 show?
    • Is there an Aarey Drugs share price target 2027 from brokerages?
    • How profitable is the business in the Aarey Drugs analyst review 2027?
    • Why does Aarey Drugs revenue swing so much?
    • Is Aarey Drugs expensive, based on the Aarey Drugs analyst review 2027?
    • What changed in shareholding during the Aarey Drugs analyst review 2027 period?
    • What should investors track after the Aarey Drugs analyst review 2027?

What Analysts Say in the Aarey Drugs Analyst Review 2027

Brokerage Rating Target Price Date
No verified coverage Not available Not available As of November 2026

We could not find a single dated, named brokerage report on Aarey Drugs. That is common for companies with a market value near ₹350 crore and little institutional ownership. It also means price moves are driven by traders and retail buyers rather than by research estimates.

Without targets, this Aarey Drugs analyst review 2027 relies on reported results, valuation ratios and shareholding data. Any figure presented elsewhere as an Aarey Drugs share price target 2027 from analysts should be treated with caution unless it names a registered research firm and a date.

Q2 FY27 Results in the Aarey Drugs Analyst Review 2027

Quarter Net Sales Net Profit Operating Margin
Sep 2026 (Q2 FY27) ₹88.62 crore ₹1.37 crore 2.40%
Jun 2026 (Q1 FY27) ₹44.63 crore ₹1.02 crore 2.98%
Mar 2026 (Q4 FY26) ₹189.47 crore ₹1.56 crore 2.29%
Dec 2025 (Q3 FY26) ₹96.43 crore ₹0.57 crore -1.57%
Sep 2025 (Q2 FY26) ₹84.16 crore ₹1.02 crore 3.14%

Sales rose about 5% from a year earlier and almost doubled from a weak June quarter. Profit of ₹1.37 crore was up about 34% from both the June quarter and the year-ago quarter. Those percentages sound strong, but the absolute numbers are small for a ₹351 crore company.

Two features of the Aarey Drugs analyst review 2027 numbers stand out. First, revenue swings sharply from quarter to quarter, from ₹44.63 crore to ₹189.47 crore within the last year. Second, operating margins sit between roughly 2% and 3%, and other income made up about 97.6% of pre-tax profit in Q2. In other words, the core business barely earns more than its costs, and the reported profit depends on non-operating income. First-half sales were also about 28.5% lower than a year earlier.

How Aarey Drugs Makes Money

Incorporated in 1990 and based in Mumbai, Aarey Drugs & Pharmaceuticals makes active pharmaceutical ingredients, also called bulk drugs, and supplies chemical products for industrial uses. Its income depends on:

  • Bulk drug volumes: orders from formulation companies that turn APIs into finished medicines.
  • Raw material spreads: the gap between input chemical prices and selling prices.
  • Trading activity: the large swings in quarterly sales suggest a meaningful trading or order-based component, though the company does not split this out in the data we reviewed.

Low margins are typical for small API suppliers without patented or specialised products. The Aarey Drugs analyst review 2027 question is whether the company can move into higher-value products.

Growth Triggers in the Aarey Drugs Analyst Review 2027

  • Fresh capital: on 30 September 2026 the company allotted 11.5 lakh shares on conversion of warrants, raising paid-up capital to ₹31.87 crore. New money can fund capacity or working capital.
  • Revenue scale: FY25 revenue was about ₹474 crore, so the business can generate large sales when orders arrive.
  • Sector support: government incentives for domestic API production aim to reduce India’s import dependence, which helps local bulk drug makers.
  • Institutional interest: domestic institutions held 1.44% in September 2026 against nil in December 2025.

Key Risks in the Aarey Drugs Analyst Review 2027

  • Thin core margins: an operating margin near 2.4% leaves almost no buffer against raw material cost increases.
  • Dependence on other income: about 97.6% of Q2 pre-tax profit came from non-operating sources.
  • Valuation: a P/E of about 84 compares with an industry figure near 52, despite low returns.
  • Low returns: return on equity is about 2.6%.
  • Volatile sales: large quarterly swings make earnings hard to predict.
  • No research coverage: without analyst scrutiny, price discovery can be erratic in both directions.

Compare Aarey Drugs With Small-Cap Pharma Peers on the Univest Screener

Aarey Drugs Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (16 Nov 2026 close) ₹111.12
52-Week High / Low ₹116.80 / ₹50.31
Market Capitalisation ₹351 crore
P/E (TTM) vs Industry 84.1 vs 52.2
Price to Book 2.07
Book Value per Share ₹53.28
Return on Equity 2.64%
Debt to Equity 0.33
FY26 Net Profit ₹3.97 crore

The price to book value of about 2.1 is not extreme on its own. The concern in this Aarey Drugs analyst review 2027 is the combination of a high P/E with a very low return on equity, which means investors are paying for profits that have not yet appeared.

Shareholding Trend

Holder Dec 2025 Sep 2026 Change
Promoters 39.05% 41.45% +2.40 pts
Foreign Investors (FII) 3.86% 4.27% +0.41 pts
Domestic Institutions (DII) 0.00% 1.44% +1.44 pts
Public 57.09% 52.83% -4.26 pts

The promoter Ghatalia family raised its stake to 41.45%, consistent with the warrant conversion. Public holding fell by more than four points, and small institutional stakes appeared for the first time. With public shareholders still owning more than half the company, retail sentiment carries a lot of weight in the Aarey Drugs analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Aarey Drugs Analyst Review 2027

  • Operating margin: any sustained move above 3% would be the first sign of real improvement.
  • Use of warrant money: whether the new capital goes into capacity or higher-value products.
  • Other income share: a falling share of non-operating income in profit would improve earnings quality.
  • Q3 FY27 sales: whether revenue stays near ₹90 crore or swings again.
  • Any research initiation: the first named brokerage note would create a real Aarey Drugs share price target 2027 benchmark.

Final Word on the Aarey Drugs Analyst Review 2027

The Aarey Drugs analyst review 2027 finds a micro-cap whose share price has more than doubled while its business continues to earn thin margins. Q2 FY27 profit of ₹1.37 crore was higher than a year ago, but it relied heavily on other income, and sales remain volatile.

With no brokerage coverage, a P/E near 84 and return on equity below 3%, the Aarey Drugs stock outlook 2027 depends on visible progress in core profitability. Investors should treat this as a higher-risk stock and verify any claims carefully. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Aarey Drugs analyst review 2027 show?

It shows no brokerage coverage and a stock that has risen about 121% from its 52-week low of ₹50.31. Q2 FY27 net sales were ₹88.62 crore and profit was ₹1.37 crore. Operating margin was only about 2.4%.

Is there an Aarey Drugs share price target 2027 from brokerages?

No verified brokerage target exists for Aarey Drugs as of November 2026. We found no dated report from a named research firm. Investors should be wary of targets that do not name a registered research house.

How profitable is the business in the Aarey Drugs analyst review 2027?

Operating margins have ranged from about -1.6% to 3.1% over the last five quarters. In Q2 FY27, about 97.6% of pre-tax profit came from other income. Return on equity is about 2.6%.

Why does Aarey Drugs revenue swing so much?

Quarterly sales moved from ₹44.63 crore in June 2026 to ₹189.47 crore in March 2026 within a year. The pattern suggests order-based or trading-linked sales. First-half FY27 sales were about 28.5% lower than a year earlier.

Is Aarey Drugs expensive, based on the Aarey Drugs analyst review 2027?

The stock trades at a P/E of about 84.1, above the industry figure of about 52.2. Its price to book is 2.07 on a book value of ₹53.28 per share. The high P/E combined with low returns means the valuation assumes a large improvement in earnings.

What changed in shareholding during the Aarey Drugs analyst review 2027 period?

Promoter holding rose to 41.45% in September 2026 from 39.05% in December 2025, in line with a warrant conversion of 11.5 lakh shares. Domestic institutions took a 1.44% stake. Public holding fell to 52.83%.

What should investors track after the Aarey Drugs analyst review 2027?

Watch whether operating margin rises above 3% and whether other income stops dominating profit. Track how the warrant money is used. The first named brokerage report, if one appears, would give a real benchmark for valuation.



2027 Aarey Drugs & Pharmaceuticals Analyst Review pharmaceuticals
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply